Navigation Links
Compact 40C CO2 Lasers

ProductsCompact 40C CO2 Lasers
Company Lumenis, Inc.
Item Compact 40C CO2 Lasers
Features Multidisciplinary. Wide range of accessories. Compact and portable. For use in hospitals, private clinics or outpatient facilities. SurgiTouch compatible for char-free, layer-by-layer tissue ablation. Designed for simplicity of operation and maximum safety. Soft touch control panel and user prompts. Alphanumeric messages walk user through each step of operation. Programmable memory protocols. Adjustable bright 5 mW He-Ne aiming beam with continuous "blinking and "off-at-lasing modes.
Description The cost-effective line of compact CO2 systems combines portability with uncompromised performance. All units feature an extremely accurate laser beam, as well as SuperPulse operation modes. These lasers are especially advantageous for small operating theatres and are easily transported to multiple office sites. Use of special contact tips and accessories allows the surgeon to apply the laser energy to target tissue. Char-free single-layer tissue ablation may be performed with any of the Lumenis CO2 systems using Lumenis' exclusive SurgiTouch scanning technology.
Info Lumenis, Inc.
Customer Service: 877-lumenis
Web site: http://www.lumenis.com

Related medicine products :

1. Compact Ultrasonic Phacoemulsification System
2. Oculus Easyfield Compact Perimeter
3. Compact 30C CO2 Lasers
4. Veris Compact
5. Compact KTP laser
6. Veris Compact™
7. Adams Compact II
8. GR 20.22 Compact High Speed Refrigerated Floor-Standing Centrifuge
9. BR 4i Compact Multi-Function Refrigerated Bench-Top Centrifuge.
10. CR 3i Compact Multi-Function Refrigerated Bench-Top Centrifuge.
11. STA Compact
Wet-Field Hemostatic Eraser Bipolar Tip (20-23 gauge Tapered/Blunt Point, Curved 150)
Wet-Field Hemostatic Eraser bipolar tip, packsize is 10/box.
Designed for explanation of foldable intraocular lenses. The instrument consists of a grooved platform that is placed under the implant and divides the implant into two pieces. The lower platform hel
Shafts angled 8 mm from tip to bend with smooth jaws. Flat, cross action handle with holes and dull finish.
Medicine Products:
(Date:5/16/2008)... - Gefitinib, the once-promising drug formerly app...also known as Iressa, enhanced the effectiveness o...ypes of metastatic breast cancer, according to a P...niversity of Texas M. D. Anderson Cancer Center. ,... first positive study for Iressa in breast cancer,...
(Date:5/16/2008)...ounces appointment of Nomura Code Securities Limit... broker, NEW YORK, May 16 /PRNewswire-FirstCall/ ...estments, Inc. (Amex: MGT ) (the "Company"), and ...Aided Detection (CAD) and,image analysis software ...,of disease, today announced the appointment of NM...
(Date:5/16/2008)...it Portland to Rally Residents to Eat Right, Move ...ts, PORTLAND, Ore., May 16 /PRNewswire/ -- The la...ifferent fad diets -- which seem to go in and out,...ong-term success has been,slim. Two out of three A...ents -- remain overweight or obese., A new campai...
(Date:5/16/2008)...of two proteins in mammalian embryos prevents the ...earchers at the Medical College of Wisconsin, Milw...the May 15 issue of Developmental Biology, was led...gy, neurobiology and anatomy at the Medical Colleg...ly identified the factors responsible for the onse...
Breaking Medicine News(10 mins):Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 2Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 3Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 2Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 3Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Oregon Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Medical College of Wisconsin researchers identify proteins that help develop mammalian hearts 2
... around the world are gathering in the West Africa...ed to claim 1,00,000 African lives every year. Po... as 'African Trypanosomiasis', the disease is carr...ing in Tsetse fly-endemic areas of west and centra...
..., a highly addictive stimulant drug, whose abuse h...he world, causes long-term changes in the human br...otor coordination, according to a study published ...s found that these effects are seen even in metham...
...s like it could be making healthy people with no h...prescribed to more than 38 million people world-wi...ies biggest success stories of recent years. Proza... SSRIs (selective serotonin reuptake inhibitors). ...
...new survey, it is found that doctors are prescribi...e throat is the second most common symptom sending...s caused by a virus and will not respond to antibi...ospital and the Stanford Center for Research in Di...
Other Medicine News:Health News:Drug abuse leads to long standing changes in the brain 2Health News:Drug abuse leads to long standing changes in the brain 3Health News:Wonder drug - could end in disaster 2
(Date:5/15/2008)... BASEL, Switzerland, May 15 /- Patie...orld,s most common cancers, can expect,further tre...Herceptin(R),(trastuzumab) following new data that...f Clinical Oncology (ASCO) annual meeting in Chica...s will attend the meeting which,is the premier eve...
(Date:5/15/2008)...Phase II Data Presented at ASCO Showed Acceptable ...ce of Grade 3 and 4 Neuropathy, WOODCLIFF LAKE, N...emotherapeutic agent eribulin mesylate (E7389) dem...ion of women with locally advanced or metastatic,b...er Phase II clinical,trial. The study also suggest...
(Date:5/15/2008)...ood pressure reductions demonstrated in Blacks, Hi...etes and Obese Individuals, PARSIPPANY, N.J., May...d today that data presented at the American Societ...c Meeting (ASH 2008) in New,Orleans demonstrated t...pine and olmesartan medoxomil) safely and effectiv...
(Date:5/15/2008)... APPENZELL, Switzerland, May 15 /- E...es Food and Drug Administration (FDA) has,granted ...ment of pulmonary,arterial hypertension (PAH). Ter...ivotal Phase II trial in Europe., "The FDA,s gran...encourages and strengthens our development program...
Breaking Medicine Technology:New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 2New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 3New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 4New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 5New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients 6Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 2Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 3Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 4Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 5Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 6Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations 7Terguride Receives FDA Orphan Drug Designation for the Treatment of Pulmonary Arterial Hypertension 2Healthcare Crisis Brought to Life in New TV Show 11337 1Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 11334 1Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 11334 2Flextronics to Acquire the FRIWO Mobile Power Business Unit of CEAG 11334 3CorVel to Present at UBS Global Healthcare Services Conference 11332 1CorVel to Present at UBS Global Healthcare Services Conference 11332 2Gene Plays Jekyll and Hyde Role in Deadly Brain Cancer 11331 1
...--Mar 19, 2007 - Nymox,Pharmaceutical Corporation ...om its newly completed long-term outcome study of ... clinical trial sites,across the U.S. and 116 unse...bo controlled study., The study assessed symptom s...207 treatment. Overall, without further NX-1207,tr...
...ata on XIENCE V Everolimus,Eluting Coronary Sten... from the ABSORB Bioabsorbable Stent Clinical Stud...-FirstCall/ --,Abbott will present data from sev... and pipeline during a number of late-breaking,c...logy,s 56th,Annual Scientific Session being held...
Other Medicine Technology:Nymox Announces Positive Results from Newly Completed Long-term,Study of NX-1207 for Benign Prostatic Hyperplasia 2Nymox Announces Positive Results from Newly Completed Long-term,Study of NX-1207 for Benign Prostatic Hyperplasia 3Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 2Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 3Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 4Abbott to Present New Data Across its Vascular Portfolio at the,American College of Cardiology's 56th Annual Scientific Session 5